Physician profile
Hillary Bailey
NPI 1154869782
$9,567.85
in general payments reported to CMS, 2019-2025
40 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,670 · 2022: $1,762 · 2023: $1,882 · 2024: $2,346 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,136.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,940.80 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,497.92 | 2021-2025 | |
| Lilly USA, LLC | $1,183.65 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $863.23 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $767.21 | 2021-2025 | Jardiance, Spiriva Respimat, Spevigo |
| Pfizer INC. | $354.88 | 2023-2025 | |
| Abbott Laboratories | $304.47 | 2021-2025 | Freestyle Libre 3, Id Now Instrument, Freestyle Libre 2 |
| Lundbeck LLC | $279.56 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $270.06 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $218.35 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $202.80 | 2021-2025 | Nexletol |
| Amgen INC. | $165.85 | 2021-2024 | Repatha |
| Otsuka America Pharmaceutical, INC. | $156.41 | 2023-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $153.84 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.56 | 2023-2025 | Caplyta |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $122.23 | 2023-2025 | Shingrix, Arexvy, Nucala |
| Grifols USA, LLC | $95.34 | 2021-2024 | Prolastin-C Liquid |
| Corcept Therapeutics | $83.14 | 2024-2025 | Korlym |
| Ibsa Pharma INC. | $74.78 | 2025 | Tirosint, Flector, Licart |
| Bausch Health US, LLC | $74.35 | 2021-2022 | |
| Janssen Biotech, INC. | $61.92 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $61.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.50 | 2021-2024 | Xifaxan, Trulance |
| Biogen, INC. | $46.32 | 2021-2022 | |
| Radius Health, INC. | $46.29 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.49 | 2022 | |
| Merck Sharp & Dohme LLC | $34.31 | 2021 | |
| Vivus LLC | $30.89 | 2023-2024 | Qsymia |
| Dexcom, INC. | $29.92 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $28.36 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $24.50 | 2024 | Veozah |
| Ucb, INC. | $21.76 | 2024 | Bimzelx |
| Exact Sciences Corporation | $20.08 | 2025 | The Cologuard Plus Collection Kit |
| Photonicare INC | $18.69 | 2023 | Otosight Middle Ear Scope |
| Acella Pharmaceuticals, LLC | $17.21 | 2025 | NP Thyroid 60 |
| Sun Pharmaceutical Industries INC. | $17.07 | 2021 | |
| Boston Scientific Corporation | $17.04 | 2024 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $15.55 | 2021 | |
| Hikma Pharmaceuticals USA | $15.53 | 2024 | Ryaltris, Kloxxado |
| Eisai INC. | $14.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.